2022 World Conference on Lung Cancer (ePosters)-EP14.05-011. Real-World Impact of Platinum Sensitivity and Disease Stage on Survival Among Medicare Patients with Small Cell Lung Cancer

EP14.05-011. Real-World Impact of Platinum Sensitivity and Disease Stage on Survival Among Medicare Patients with Small Cell Lung Cancer

Back to course

Pdf Summary

This study sponsored by Ipsen investigated the real-world impact of platinum sensitivity and disease stage on survival among Medicare patients with small cell lung cancer (SCLC). The researchers identified patients diagnosed with SCLC in 2017 and examined their survival rates over time based on disease stage and platinum sensitivity. The study included patients who had a lung cancer diagnosis, were continuously enrolled in Medicare from the month before diagnosis through 2020 or death, and were treated with first-line platinum-based regimens. Patients with certain exclusion criteria were not included in the analysis.<br /><br />The study found that overall, 91% of patients with SCLC survived at least 90 days, 82% survived at least 180 days, and 74% survived at least 360 days post-diagnosis. Patients with extensive-stage disease had poorer survival compared to those with limited-stage disease. Platinum sensitivity was found to be the best indicator of survival across all time periods. Patients with platinum-sensitive SCLC, regardless of disease stage, had a 99% survival rate at least one year post-diagnosis. In contrast, patients with platinum-refractory limited disease had a 63% survival rate, and patients with platinum-refractory extensive disease had a 49% survival rate.<br /><br />The study also found that patients with platinum-refractory extensive-stage disease had the poorest survivorship. They had a 46% lower likelihood of surviving at least one year post-diagnosis compared to platinum-sensitive patients. <br /><br />The study has a few limitations, and the results are based on the analysis of Medicare data from 2016 to 2020. The findings highlight the importance of considering platinum sensitivity and disease stage in determining survival outcomes for patients with SCLC.

Asset Subtitle

Paul Cockrum

Meta Tag

Speaker Paul Cockrum

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - RW/SOC

Keywords

platinum sensitivity

disease stage

survival

Medicare patients

small cell lung cancer

SCLC

real-world impact

first-line platinum-based regimens

limited-stage disease

extensive-stage disease